Medical/Pharmaceuticals

Hong Kong Pharma Digital Technology Holdings Limited Announces Pricing of Initial Public Offering

NEW YORK, Jan. 14, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited ("Hong Kong Pharma" or the "Company"), a leading provider of OTC pharmaceutical cross-border e-commerce supply chain services inHong Kong, today announced the pricing of its initial public offering (the "...

2025-01-15 02:01 2030

South Korea's WIRobotics Takes the Spotlight at CES 2025, Plans Global Expansion

YONGIN, South Korea, Jan. 14, 2025 /PRNewswire/ -- WIRobotics, the company behind the revolutionary wearable mobility solutionWIM(We Innovate Mobility), has achieved a major milestone at CES 2025, one of the world's premier technology trade shows. Featuring more than 4,500 companies from 166 coun...

2025-01-15 01:00 3164

TraceLink Wins 2024 Merit Award for Technology in HealthTech Category for Second Consecutive Year

BOSTON, Jan. 15, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the supply chain, is proud to announce its recognition as a winner of the 2024 Merit Awards for Technology in the HealthTech category. This marks the second consecutiv...

2025-01-15 00:42 1967

Metabolon Appoints Michael Irwin as Vice President, Global Head of Sales

Michael Irwin will drive Metabolon's global sales strategy as the company moves into its next phase of growth in the mutliomic marketplace MORRISVILLE, N.C., Jan. 14, 2025 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life scie...

2025-01-14 22:00 1794

Endogenex™ Appoints Krissy Wright as Chief Financial Officer

Bringing finance, operational, and corporate development expertise to an experienced leadership team. MINNEAPOLIS, Jan. 15, 2025 /PRNewswire/ -- Endogenex, Inc., a clinical-stage medical device company, is proud to announce the addition ofKrissy Wright as Chief Financial Officer (CFO). In this r...

2025-01-14 21:32 2039

Argon Medical Expands Oncology Product Offering with Acquisition of the SeQure® and DraKon™ Microcatheters

PLANO, Texas, Jan. 14, 2025 /PRNewswire/ -- Argon Medical, a leading provider of medical device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology procedures, announces the acquisition of certain assets of Accurate Medical Therapeutics, Ltd., the man...

2025-01-14 21:05 2278

ImmunoForge Receives IND Approval for Phase 2 Clinical Trial of 'Pemziviptadil' for DMD Cardiomyopathy Treatment from FDA, and KF1601, a chronic myeloid leukemia treatment, phase 1 clinical trial IND approved by MFDS

SEOUL, South Korea, Jan. 14, 2025 /PRNewswire/ -- ImmunoForge announced that it has received approval for the Phase 2 clinical trial IND for 'Pemziviptadil (development code name PF1804),' a treatment for DMD (Duchenne Muscular Dystrophy) cardiomyopathy, from the U.S. Food and Drug Administration...

2025-01-14 21:00 2857

Clarivate Launches DRG Fusion - A New Life Sciences Analytics Product Powered by Real-World Data

New modular analytics solution empowers commercial teams to optimize strategies and improve patient outcomes LONDON, Jan. 14, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of DRG Fusion, an innovative platform ...

2025-01-14 16:10 2095

Malaysian Society for Quality in Health (MSQH) Earns Global Recognition for its Organisational and Surveyor Training Programme Accreditation

KUALA LUMPUR, Malaysia, Jan. 14, 2025 /PRNewswire/ -- The Malaysian Society for Quality in Health (MSQH), a leading national healthcare accreditation body dedicated to ensuring the highest standards of quality and safety in healthcare services, proudly announces its successful re-certification fo...

2025-01-14 08:00 3498

Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference

MELBOURNE, Australia and INDIANAPOLIS, Jan. 14, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today advises that Dr.Christian Behrenbruch, Managing Director and Group CEO, will be presenting this week at the 43rd Annual J.P. Morgan Healthcare Confe...

2025-01-14 05:43 2449

MicroAire appoints Remco Maljers as Head of International Sales

CHARLOTTESVILLE, Va., Jan. 14, 2025 /PRNewswire/ -- MicroAire Surgical Instruments, a Marmon Holdings | Berkshire Hathaway company focused on plastic and upper extremity surgery, is pleased to announce the appointment ofRemco Maljers as its Head of International Sales. Remco brings with him exte...

2025-01-14 03:00 2275

BioCina and NovaCina Merger Bolsters Global CDMO Industry

ADELAIDE, South Australia and PERTH, Western Australia, Jan. 14, 2025 /PRNewswire/ -- Global Contract Development and Manufacturing Organizations (CDMOs) BioCina and NovaCina announced a strategic merger that will create a powerful brand in biopharmaceutical and small molecule contract manufactur...

2025-01-14 00:43 2880

Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currentl...

2025-01-13 22:05 2995

Dx&Vx Presents a New Paradigm for Next-Generation Infectious Disease Response with the Development of a Universal Vaccine

- Preparing for Phase 2 Global Trials of a Ferritin Platform-Based Virus-Like Particle Universal Coronavirus Vaccine - Based on the Excellent Safety and Immune Response in Phase 1 Clinical Results, with a Plan to Extend Administration Routes and Indications SEOUL, South Korea, Jan. 13, 2025 /PRNe...

2025-01-13 22:00 3358

ZEISS MEL 90 excimer laser receives U.S. FDA approval; completes Corneal Refractive Workflow

The excimer laser complements the ZEISS VISUMAX 800 with ZEISS SMILE pro, extending ZEISS' LVC market leadership with treatment for myopia, hyperopia, and mixed astigmatism. DUBLIN, Calif. and JENA, Germany, Jan. 13, 2025 /PRNewswire/ -- ZEISS Medical Technology announced today that theMEL® 90 r...

2025-01-13 22:00 2418

Neuromodulation Wristband ObeEnd Reduces Heart Rate and Perceived Exercise Exertion

VANCOUVER, BC, Jan. 13, 2025 /PRNewswire/ -- WAT Medical Enterprise collaborated withConcordia University and Mitacs Canada to conduct a study using ObeEnd, the neuromodulation device designedby WAT for weight and health management. The study revealed that electroacupuncture may help improve exe...

2025-01-13 22:00 2222

CARsgen's Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial

SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that KJ-C2219, an allogeneic CAR T-cell therapy targeting CD19/CD20, ...

2025-01-13 21:50 2131

CBC Group's R-Bridge Announces US$40M Synthetic Royalty-Backed Financing for Mirxes to Advance Global Expansion

-  R-Bridge will provide bespoke financing of US$40 million with a synthetic royalty structure and flexible repayment terms -  Financing will accelerate Mirxes, Singapore -based miRNA tech company's innovation and commercialization of cancer early detection solutions in new markets -  Transacti...

2025-01-13 19:25 3211

XingImaging Opens State-of-the-Art Research Facility in New Haven, Connecticut

NEW HAVEN, Conn., Jan. 13, 2025 /PRNewswire/ -- XingImaging, a MITRO company, a leader in advanced research imaging and radiopharmaceutical services, is excited to announce the opening of its new state-of-the art research facility in New Haven, Connecticut. The facility includes a clinic to recrui...

2025-01-13 18:00 1692

Telix Exceeds FY24 Guidance with US$142M Q4 Revenue

MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today provides an update on its commercial and operational performance for the quarter ended31 December 2024 (Q4 2024). Sustained revenue growth * Q...

2025-01-13 15:12 3493
1 ... 131132133134135136137 ... 646

Week's Top Stories